GWM
SUPN icon

Gilpin Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Gilpin Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$216 Sell
5
-3
-38% -$137 ﹤0.01% 1099
2026
Q2 		$373 Sell
8
-2
-20% -$96 ﹤0.01% 766
2026
Q1 		$517 Buy
10
+5
+100% +$255 ﹤0.01% 605
2025
Q4 		$249 Buy
+5
New +$243 ﹤0.01% 597

Other funds holding SUPN

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's SUPN Position: Q3 2026 in Review

Gilpin Wealth Management reduced its Supernus Pharmaceuticals (SUPN) stake by 38% in Q3 2026, selling an estimated $137 and leaving 5 shares worth $216. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

Gilpin Wealth Management first reported a position in SUPN in Q4 2025 and has held it in 4 quarters since. The position peaked at $517 in Q1 2026. 8 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.

  • Gilpin Wealth Management held 5 shares of Supernus Pharmaceuticals worth $216 as of Q3 2026.
  • Gilpin Wealth Management sold 3 Supernus Pharmaceuticals shares in Q3 2026, an estimated $137.
  • Supernus Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1099 holding.
  • Gilpin Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Supernus Pharmaceuticals position peaked at $517 in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.